Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Phase II Study of Perioperative Zimberelimab + Domvanalimab and Neoadjuvant Chemotherapy in Locally Advanced, Resectable, Gastroesophageal Adenocarcinoma

NCT07283848 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07283848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07283848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Phase II Study of Perioperative Zimberelimab + Domvanalimab and Neoadjuvant Chemotherapy in Locally Advanced, Resectable, Gastroesophageal Adenocarcinoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
February 1, 2026
Completion date
December 1, 2029
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma gastroesophageal junction, adenocarcinoma stomach